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Abstract
Pseudomonas aeruginosa produces a number of proteases that are associated with virulence and disease
progression. A substrate able to detect P. aeruginosa-specific proteolytic activity could help to rapidly alert clinicians
to the virulence potential of individual P. aeruginosa strains. For this purpose we designed a set of P. aeruginosa-
specific fluorogenic substrates, comprising fluorescence resonance energy transfer (FRET)-labeled peptides, and
evaluated their applicability to P. aeruginosa virulence in a range of clinical isolates. A FRET-peptide comprising
three glycines (3xGly) was found to be specific for the detection of P. aeruginosa proteases. Further screening of 97
P. aeruginosa clinical isolates showed a wide variation in 3xGly cleavage activity. The absence of 3xGly degradation
by a lasI knock out strain indicated that 3xGly cleavage by P. aeruginosa could be quorum sensing (QS)-related, a
hypothesis strengthened by the observation of a strong correlation between 3xGly cleavage, LasA staphylolytic
activity and pyocyanin production. Additionally, isolates able to cleave 3xGly were more susceptible to the QS
inhibiting antibiotic azithromycin (AZM). In conclusion, we designed and evaluated a 3xGly substrate possibly useful
as a simple tool to predict virulence and AZM susceptibility.
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Introduction
Pseudomonas aeruginosa, is a gram-negative rod-shaped
bacterium, which is an important cause of infection in
individuals suffering from a wide range of underlying disease
conditions, including individuals with a compromised host
defence, burn patients and in patients suffering from the
genetically inherited respiratory tract disease cystic fibrosis
(CF). P. aeruginosa is also a frequent cause of hospital
acquired pneumonia, wound infections and bacteraemia [1].
Early detection of a P. aeruginosa infection facilitates effective
antimicrobial treatment, reduces inappropriate antibiotic
prescription and could possibly contribute to preventing
irreversible lung disease in CF patients. Additionally, this
bacterial pathogen produces a number of protease enzymes
that are associated with virulence and disease progression [2].
In this respect, a substrate able to detect P. aeruginosa-
specific proteolytic activity could help to rapidly alert clinicians
to the virulence potential of individual P. aeruginosa strains
isolated from different patients. Specifically, detection of these
protease virulence factors could potentially be used to monitor
the severity of infection and to predict disease outcome,
thereby providing useful information to support tailor-made
patient monitoring and treatment, a first step towards
introducing “personalized medicine”.
In theory, bacterial proteases may be suited as biomarkers
for the rapid and sensitive identification of microorganisms in
clinical samples. Further, the ability to utilize protease based
detection methods to diagnose bacterial infections has been
previously described [3,4]. In this respect, it is known that P.
aeruginosa is equipped with a large arsenal of virulence factors
that aid to successfully infect the host [2]. The majority of these
virulence factors include proteases produced under control of
the Las and Rhl quorum sensing (QS) systems of P.
aeruginosa [5], examples of which include LasA and LasB
elastases and alkaline protease [6]. These proteases play an
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important role in P. aeruginosa pathogenesis through the
degradation of biologically active proteins present in human
tissue [7]. In fact, the significant role of the QS-system in P.
aeruginosa-related disease progression has resulted in much
research into QS-inhibiting compounds that could potentially
reduce the organism’s virulence potential [8–12]. Further, the
therapeutic efficacy of this anti-QS, anti-virulence, strategy in
the treatment of P. aeruginosa has already been demonstrated
for the QS-inhibiting antibiotic azithromycin [12]. Though anti-
virulence treatment based on QS-inhibition is only useful when
an active, virulence factor secreting, QS-system is present in
the P. aeruginosa strain to be targeted.
In this study we describe the design of a novel P.
aeruginosa-specific Fluorescence Resonance Energy Transfer
(FRET)-peptide substrate and examine its applicability for the
detection of P. aeruginosa proteolytic activity in clinical
specimens. In addition, we studied the link between substrate
cleavage efficiency, virulence factor production and
susceptibility towards QS-inhibiting antibiotics, such as
azithromycin.
Materials and Methods
Bacteria
The P. aeruginosa strains used for substrate specificity
testing are listed in Table 1. Clinical strains of P. aeruginosa
were collected from a bacterial biobank present within the
Department of Medical Microbiology and Infectious Diseases of
the Erasmus Medical Center, Rotterdam, Netherlands,
collected between the years 2008-2012. In total 97 clinical
isolates were selected; 13 from blood, 56 from sputum (35 CF
patients and 21 non-CF patients), and 28 strains were isolated
from wounds. The VITEK 2 system (bioMérieux, Marcy
L`Etoile, France) was used for identification and antibiotic
susceptibility testing of the clinical isolates. For the preparation
of culture supernatants, all bacteria were grown in 5 ml Brain
Heart Infusion (BHI) medium (bioTrading, Mijdrecht, The
Netherlands) at 37 °C. After 16 h of culture, the bacteria were
pelleted by centrifugation for 10 min at 3000 x g, and the
enzyme containing supernatant was filter sterilized through a
0.22 μm filter (Millipore, Amsterdam, The Netherlands).
FRET- assay
The substrates used in this study were purchased at
PepScan Presto B.V. (Lelystad, The Netherlands) with a purity
> 90%. All substrates were C-terminally flanked with a
fluorescent probe; FITC and N-terminally flanked with a lysine
coupled quencher; Dabcyl. Identity of the substrates was
confirmed by PepScan Presto B.V. using mass spectrometry.
Assays were performed in black, clear bottom 96-well plates
(Corning, Lowell, USA). Proteolytic activity was determined by
incubating 16 μM substrate with 50 μl filtered bacterial culture
supernatant or 50 µl lysostaphin (0.04 µg/µl diluted in BHI,
Sigma, Zwijndrecht, The Netherlands) at 37 °C. Filtered BHI
medium was used as a negative control. Plates were read for
60 min with 2 min intervals using a fluorescence microplate
reader (FLUOstar Galaxy, BMG Laboratories, Offenburg,
Germany) using an excitation wavelength of 485 nm and an
emission wavelength of 530 nm. Relative fluorescence (RF)
values were obtained after correction against an un-inoculated
BHI culture medium control. Protease activity was defined in
RF per minute (RF/min).
Sensitivity testing of the 3xGly substrate in vitro
P. aeruginosa PAO1 was cultured overnight in BHI medium
at 37 °C. Next day, 20 µl of the overnight culture was added to
20 ml fresh BHI medium. Subsequently, bacteria were grown
for another 16 h and a sample was taken every hour. The
number of bacteria in the sample was determined by colony
counting by plating 10-fold serial dilutions on trypticase soy
agar (TSA) plates (bioTrading, Mijdrecht, The Netherlands).
Plates were incubated at 37 °C and bacteria were enumerated
after overnight incubation. Proteolytic activity on the 3xGly
substrate was examined using 50 µL samples in the FRET-
assay as described above. Relative fluorescence (RF) values
were obtained after correction against negative culture medium
samples. The protease activity was defined in RF per minute
(RF/min). Proteolytic activity with an RF/min > 5 was defined
positive.
Quantification of pyocyanin production and LasA
protease activity
Extracellular pyocyanin production was determined as
previously described [13]. LasA protease activity was examined
by measuring the ability of stationary phase P. aeruginosa
culture supernatants (see FRET-assay section above) to lyse
heat-killed Staphylococcus aureus cells as described by
Kessler et al [14].
RNA isolation and cDNA synthesis
A selection of 12 P. aeruginosa isolates were chosen for
RNA isolation. These isolates had been cultured from blood,
wound and sputum clinical specimens, with two isolates that
were 3xGly active (+, RF/min > 5) and two isolates that were
3xGly inactive (-, RF/min < 5), being chosen from each clinical
Table 1. Bacterial strains used in this study.
Strain  
Pseudomonas aeruginosa ATCC 15692, PAO1
Pseudomonas aeruginosa PA14
Pseudomonas aeruginosa PA14ΔlasI [31]
Pseudomonas fluorescens Clinical isolate
Pseudomonas putida S12
Pseudomonas stutzeri DSMZ 10701, JM300
Staphylococcus aureus ATCC 43300
Staphylococcus simulans ATCC 27851
Staphylococcus capitis subsp. capitis ATCC 35661
Staphylococcus epidermidis Clinical isolate
Streptococcus pneumoniae ATCC 49619
Streptococcus equi subsp. zooepidemicus ATCC 43079
Klebsiella pneumoniae ATCC 43816
Haemophilus influenzae ATCC 49247
doi: 10.1371/journal.pone.0081428.t001
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specimen type .P. aeruginosa strain PAO1 (ATCC 15692) was
used as a 3xGly positive reference control. The 12 P.
aeruginosa isolates were initially grown overnight in BHI
medium at 37°C,. Next day the overnight culture was diluted
1:10 in BHI medium and the bacteria again cultured at 37 °C
until an OD600 of approximately 0.9 - 1.0 was reached. From
these cultures total RNA was extracted using the FastRNA
ProBlue kit (Promega, Leiden, The Netherlands) according to
manufacturer’s instructions. To remove any contaminating
DNA, 1 μg of extracted RNA was mixed with one unit DNase
(Fermentas, Thermo Fisher, Landsmeer, The Netherlands) in
1x DNase reaction buffer. The mixture was then incubated at
37 °C for 30 min and the reaction stopped by the addition of 1
μl 50 mM EDTA and subsequent incubation for 10 min at 65
°C. For cDNA synthesis, DNase treated RNA (500 ng) was
incubated for 60 min at 42 °C with 5 µM random hexamer
primers, 10 units Ribolock, 1 mM dNTPs and 200 units
RevertAid in 1x reaction buffer (Fermentas, Thermo Fisher,
Landsmeer, The Netherlands). The reaction was stopped by
incubation at 70 °C for 5 min.
Expression of quorum sensing genes
The detection of QS-gene expression was performed using
real-time PCR amplification and specifically designed primers
for the QS-related pathway genes lasI and rhlA, the non-QS
related control gene trpD and the P. aeruginosa housekeeping
gene rpsL [15–17]. Each PCR contained 1x FastStart SYBR
Green mastermix (Roche, Woerden, The Netherlands), 4 mM
MgCl2 and 0.5 pmol of each primer and 2 μl of 10x diluted
cDNA. Amplification was performed using the LightCycler
(Roche, Woerden, The Netherlands) The cycling parameters
used were: 15 min at 95 °C, 40 amplification cycles of 95 °C for
20 s, 60 °C for 20 s and 72 °C for 30 s. Melting curve analysis,
performed at the end of amplification, showed a single product
peak, indicating that no non-specific products were amplified.
Data were analyzed using LightCycler software (version 3.0)
and the housekeeping gene rpsL was used as a reference
(housekeeping) gene for normalizing gene expression. The 2-
ΔΔCt method was used to calculate the expression of the genes
of interest [18]. QS-gene expression was calculated as a
Figure 1.  Cleavage activity of lysostaphin and P. aeruginosa culture supernatant on a range of glycine
substrates.  Lysostaphin (2 µg, grey bar) and culture supernatant of P. aeruginosa PAO1 (white bar) were incubated with 16 µM
FRET-substrate at 37 °C for 1 h. Cleavage of the substrates was defined in Relative Fluorescence per minute (RF/min). Results are
expressed as mean ± SEM (n = 3).
doi: 10.1371/journal.pone.0081428.g001
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relative percentage of the rpsL-normalized gene expression in
the control P. aeruginosa PAO1 isolate.
Azithromycin susceptibility testing
The susceptibility of P. aeruginosa to the QS inhibiting
antibiotic azithromycin (AZM) was evaluated for 35 P.
aeruginosa strains isolated from the sputa of CF-patients using
the disc diffusion method. For this purpose, a suspension of
each bacterial isolate, overnight grown on tryptic soy agar
(TSA) blood agar, was prepared in physiological saline at a
turbidity of 0.5 McFarland units. Each bacterial suspension was
streaked onto TSA plates with a sterile cotton swab, to obtain
uniform bacterial growth, and a disc containing 15 µg AZM
(Oxoid, Badhoevedorp, The Netherlands) was placed on the
middle of the inoculated culture plate. Plates were then
incubated at 37 °C, incubated overnight and the diameter of the
zones of growth inhibition (mm) were measured.
Results
Design of P. aeruginosa- specific FRET-substrates
In a study by Vessillier et al. it was described that the P.
aeruginosa specific protease LasA, recognizes and degrades
glycine bonds [19]. Based on these cleavage characteristics we
designed FRET-peptide substrates, comprising multiple glycine
residues, and incubated these substrates with P. aeruginosa
culture supernatant. These substrates included FITC-Gly-
LysDbc (1xGly), FITC-(Gly)2-LysDbc (2xGly), FITC-(Gly)3-
LysDbc (3xGly), FITC-(Gly)4-LysDbc (4xGly) and FITC-(Gly)5-
LysDbc (5xGly). As a specificity control, we compared the
activity of P. aeruginosa culture supernatant towards these
substrates with cleavage activity with lysostaphin, an enzyme
produced by Staphylococcus simulans, that recognizes and
degrades penta-glycine bonds [20]. Experiments showed that
the 5xGly substrate was cleaved by both lysostaphin and P.
aeruginosa culture supernatant, and that a similar result was
observed for the substrate containing four glycines (Figure 1).
However, when the 3xGly substrate was tested, a significant
decrease in proteolytic activity by lysostaphin was observed,
whereas the proteolytic activity of P. aeruginosa actually
significantly increased. Additional experiments showed minimal
cleavage in case of the 2xGly substrate and no cleavage using
the 1xGly substrate. These results indicated that the 3xGly
substrate was the best candidate, amongst the substrates
tested, to investigate as a potential substrate for the rapid
detection of virulence in P. aeruginosa.
Characterization of 3xGly substrate cleavage
To characterize the specificity of the 3xGly substrate, we
examined 3xGly cleavage using a range of culture
supernatants (i) from a range of Pseudomonas non-aeruginosa
species, and (ii) from a range of additional respiratory bacteria,
and microorganisms known to produce lysostaphin (-like)
proteases (Table 1). Results showed that the 3xGly substrate
was exclusively cleaved by culture supernatants of P.
aeruginosa (strains PA14 and PAO1), but not by P. putida, P.
stutzeri or P. fluorescens. Further, no cleavage activity was
observed for the range of additional respiratory bacteria, and
microorganisms known to produce lysostaphin, that were
tested. Interestingly, no cleavage activity was observed when
Figure 2.  Specificity testing of the 3xGly substrate.  Culture supernatants of Pseudomonas spp., respiratory microorganisms
and bacteria producing lysostaphin (*) or lysostaphin-like (**) proteases were incubated with 16 µM 3xGly. Fluorescence was
measured for 1 h at 37 °C. Results are expressed as mean ± SEM (n = 3).
doi: 10.1371/journal.pone.0081428.g002
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the 3xGly substrate was incubated with culture supernatant of
the P. aeruginosa strain PA14∆lasI which lacks the lasI QS-
gene (Figure 2). Besides the above mentioned bacteria the
3xGly substrate was screened with an additional set of in total
17 bacterial supernatants. None of these bacteria was able to
cleave the substrate (data not shown). To characterize 3xGly
sensitivity, the substrate was incubated with a dilution series of
P. aeruginosa PAO1. Using a cut-off of RF/min > 5, it was
observed that the limit of detection for P. aeruginosa PAO1
using the 3xGly substrate was 107 CFU//ml (Figure 3).
In order to obtain a more comprehensive view of protease
activity in an extended range of clinically relevant P.
aeruginosa isolates, we tested a total of 97 randomly selected
P. aeruginosa clinical isolates that had been cultured from
wounds, blood and sputum. These strains were analyzed for
their supernatant cleavage activity on the 3xGly substrate.
Results revealed that a large percentage of the strains tested
(60/97; 62%) were unable to cleave the 3xGly substrate. This
percentage varied between clinical specimens from 50% in
wound isolates to 73% in isolates from CF patients (Table 2).
Relationship between 3xGly cleavage and virulence
LasA is a member of the beta-lytic endopeptidase family and
pyocyanin is a secondary metabolite which has the ability to
oxidize and reduce other molecules [21,22]. The expression of
both of these virulence factors by P. aeruginosa has been
shown to be related to its QS system [2]. Results from both
LasA and pyocyanin production indicated that both were
significantly higher in 3xGly cleaving P. aeruginosa isolates,
though some variation in individual isolates was observed
(Figure 4A-B). The association between LasA activity and
3xGly cleavage was very significant (P < 0.0001, r = 0.542).
Relationship between 3xGly cleavage and the quorum
sensing system
The observation of a lack of 3xGly activity using a P.
aeruginosa lasI knock-out mutant strain (Figure 1) indicated
that an absence of 3xGly cleavage activity might be related to
an impaired QS-system expression. In order to verify this
hypothesis we investigated the expression of the QS-genes
lasI and rhlA using a selection of 3xGly cleaving and non-
Figure 3.  Sensitivity testing of the 3xGly substrate.  Serial dilutions of P. aeruginosa PAO1 were incubated with 16 µM 3xGly at
37 °C. Cleavage activity was defined in Relative Fluorescence per minute (RF/min). The cut-off of the assay was estimated at an
RF/min of 5. Results are expressed as mean ± SEM (n = 3).
doi: 10.1371/journal.pone.0081428.g003
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cleaving P. aeruginosa isolates. The strains which lacked
3xGly proteolytic activity showed a reduced expression of lasI
and rhlA when compared to lasI and rhlA expression in 3xGly
cleaving isolates. A significant reduction in normalized lasI, but
not rhlA, was observed (P = 0.05). There was no difference
observed in the normalized expression of the trpD control, a
gene unrelated to the QS-system (Figure 5).
Relationship between 3xGly cleavage and azithromycin
susceptibility
The apparent association between 3xGly cleavage and the
QS-system led us to investigate a possible relationship
between 3xGly cleavage and susceptibility to the QS-inhibiting
antibiotic AZM. We examined the AZM susceptibility of P.
aeruginosa clinical isolates using a disc diffusion assay, but
found no relationship between 3xGly cleavage and AZM
susceptibility for P. aeruginosa isolates cultured from blood and
wounds, or from the sputum of non-CF patients. Interestingly
however, a highly significant association was observed
between AZM inhibition zone and 3xGly cleavage for P.
aeruginosa isolates cultured from the sputa of CF patients
(Figure 6). Finally, 3xGly cleavage in relation to a range of AZM
unrelated antibiotic resistances was investigated, with no
significant correlation being found between 3xGly cleavage and
resistance to the other antibiotics tested. However, it was noted
that among the group of P. aeruginosa isolates that lacked
3xGly cleavage more multi drug resistant (MDR) isolates were
observed (Table S1).
Discussion
We designed and evaluated a fluorogenic substrate as a
potential marker of virulence in the bacterial pathogen P.
aeruginosa. Preliminary experiments indicated that this 3xGly
substrate was specific for cleavage by P. aeruginosa, and that
the sensitivity of the substrate was 107 CFU/ml within 1 h,
though this limit of detection may vary among different P.
aeruginosa strains (it was observed that PA14 cleaved the
3xGly substrate more efficient than PAO1). Only slight cross
reactivity was observed with another bacterial protease,
lysostaphin, which recognizes and degrades pentaglycin bonds
[20]. Later experiments using a broader range of 97 clinical
isolates showed that 3xGly cleavage activity differed between
P. aeruginosa isolates, with a large percentage of the isolates
being unable to cleave the 3xGly substrate. This is possibly
related to difference in expression of the P. aeruginosa QS-
system. We indeed observed a slight, but non-significant,
decrease in expression of the QS-genes lasI and rhlI in P.
aeruginosa strains which lacked 3xGly proteolytic activity.
Because this experiment was performed with a subset of the P.
aeruginosa strains future experiments are required in order to
identify the exact genetic basis of the proteolysis / virulence
correlation.
One of the most important proteases secreted under the
direction of the P. aeruginosa QS system is the LasA protease.
The LasA protease (staphylolysin) of P. aeruginosa can
recognize and degrade glycine bonds, degrade elastin and is
an important contributor to the pathogenesis of this organism.
LasA (20 kDa) is a member of the beta-lytic endopeptidase
family of extracellular bacterial proteases, and possesses high-
level staphylolytic activity [7]. Further, Elston et al. showed that
Figure 4.  Link between 3xGly cleavage and secretion of QS-related proteins.  Culture supernatants of 56 P. aeruginosa strains
isolated from sputum were analyzed for LasA protease activity (A) and pyocyanin production (B). QS-related LasA cleavage activity
in 3xGly cleaving P. aeruginosa strains (RF/min > 5) was compared to LasA cleavage in 3xGly non-cleaving strains (RF/min < 5)
using the unpaired, two-tailed students t-test (** P < 0.01, *** P < 0.0001). A horizontal line indicates the median LasA activity /
pyocyanin production.
doi: 10.1371/journal.pone.0081428.g004
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the LasA protease is capable of the degradation of peptides in
which three glycines were present [23]. Therefore, based on
the already established glycine-cleaving proteolytic activity of
the P. aeruginosa LasA protease, its staphylolytic activity, its
control via the P. aeruginosa QS system, and the results
observed for 3xGly cleavage, it appears that the LasA protease
is most likely the protease virulence factor measured in P.
aeruginosa culture supernatant using our 3xGly substrate, but
this needs to be confirmed experimentally.
Other factors, dependent on the expression of the QS-
system of P. aeruginosa are pyocyanin production and
antibiotic resistance. Pyocyanin is an important virulence factor
and functions as an electron transfer facilitator [2]. In addition,
P. aeruginosa isolates which lack production of QS-dependent
virulence factors, have previously been shown to possess a
higher resistance rate to antimicrobials, among which
ciprofloxacin and tobramycin [24]. Although, we indeed
observed a significant correlation between pyocyanin
production and 3xGly cleavage, no significant correlation with
resistance to the antimicrobials examined was found (Table 1).
This discrepancy might be due to difference in culture
conditions, as the secretion of QS-metabolites, such as the
LasA protease, depends on the availability of nutrients in the
environment [25].
Perhaps one of the most interesting findings of the study was
the fact that the highest percentage of 3xGly non-cleaving
isolates was observed in group of CF sputum isolates. This is
possibly due to the fact that CF patients are often colonized
with P. aeruginosa [26]. Kohler et al showed that during P.
aeruginosa colonization of intubated patients the number of
QS- mutants increases. These mutants lack the production of
QS-dependent proteins, such as elastase and rhamnolipids,
and take advantage of the “public goods” produced by wild-
type isolates that reside within the total population of P.
aeruginosa isolates that colonize the patient (“cheater” strains).
This phenomenon may result in overgrowth of the wild-type P.
aeruginosa isolate by the mutant isolate due to its fitness
benefit [27].
Currently, research is being performed to investigate the
potential of QS-inhibiting compounds in the treatment of P.
aeruginosa related infections [8–12]. The most thoroughly
investigated QS-inhibiting antibiotic is AZM. AZM treatment is
associated with improvement in disease outcome in P.
aeruginosa infected CF-patients [28]. However, an anti-
virulence agent such as AZM is only effective when an active,
virulence factor secreting, QS-system is present. For this
reason Kohler et al screened for rhamnolipid production to
select patients for their clinical trial on AZM efficiency. Patients
Figure 5.  Link between 3xGly cleavage and expression of QS-genes.  QS-gene expression was determined in a subset P.
aeruginosa strains as described in material and methods. Normalized expression of the QS-circuit gene lasI, QS-target gene rhlA
and the QS-independent gene trpD measured in mid-log phase grown bacteria is shown as relative values (%) compared to the P.
aeruginosa PAO1 control strain. A horizontal line indicates the median expression levels. P-values were calculated using unpaired,
two-tailed students t-tests.
doi: 10.1371/journal.pone.0081428.g005
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infected with P. aeruginosa strains which are unable to produce
these QS-proteins were excluded from the protocol [12].
We observed a strong correlation between AZM
susceptibility and 3xGly cleavage by P. aeruginosa isolates
cultured from the sputum of CF patients, with growth inhibition
zones in the 3xGly cleavage-positive isolates being significant
larger compared to zones of 3xGly cleavage-negative isolates.
Until recently it was stated that AZM is unable to eradicate P.
aeruginosa by bacterial killing [29]. A recent publication by
Buyck et al. however, revealed that growth inhibition of P.
aeruginosa by AZM depends on the medium used [30]. P.
aeruginosa strains grown in Mueller Hinton medium have a
lower outer membrane permeability compared to strains
cultured in for example RPMI. This results in an increase in
susceptibility towards AZM and thus might explain the
presence of AZM induced growth inhibition zones we observed
on TSA agar plates.
In conclusion, we designed and evaluated a novel 3xGly
FRET-peptide substrate for the assessment of virulence in P.
aeruginosa. Cleavage of the 3xGly FRET-substrate was
Table 2. 3xGly cleavage activity among 97 randomly
selected P. aeruginosa clinical isolates a.
   Sputum
   (n=56)
 Wound Blood CF Non-CF
 (n=28) (n=13) (n=35) (n=21)
Cleavage 14 (50) 4 (31) 9 (27) 10 (48)
No cleavage 14 (50 9 (69) 26 (73) 11 (52)
a. Number in brackets denotes percentage (%)
doi: 10.1371/journal.pone.0081428.t002
Figure 6.  Link between 3xGly cleavage and azithromycin susceptibility.  Azithromycin (AZM) susceptibility of P. aeruginosa
isolates cultured from sputum was determined using the disc diffusion method. AZM inhibition zones for 3xGly cleaving (RF/min > 5)
P. aeruginosa strains was compared to inhibition zones of 3xGly non-cleaving strains (RF/min < 5) using the unpaired, two-tailed
students t-test (*** P < 0.0001). A horizontal line indicates the median AZM inhibition zone size.
doi: 10.1371/journal.pone.0081428.g006
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significantly associated with culture supernatant protease
activity, staphylolytic activity, pyocyanin production and the
expression of lasI in the P. aeruginosa QS system. This
publication represents the first step in the development of a
simple test to determine and monitor P. aeruginosa virulence in
clinical samples, including the prediction of the effectiveness of
QS-inhibiting antibiotic treatments. Preliminary evaluation
experiments suggest that this methodology may achieve its
greatest potential when monitoring CF patients colonized by,
and undergoing treatment for, P. aeruginosa infections.
Supporting Information
Table S1.  Antibiotic susceptibility of the 97 P. aeruginosa
strains used in this study.
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